WO2007070547A3 - Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid - Google Patents

Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid Download PDF

Info

Publication number
WO2007070547A3
WO2007070547A3 PCT/US2006/047474 US2006047474W WO2007070547A3 WO 2007070547 A3 WO2007070547 A3 WO 2007070547A3 US 2006047474 W US2006047474 W US 2006047474W WO 2007070547 A3 WO2007070547 A3 WO 2007070547A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
arthritis
treatment
derivative
crosslinked hyaluronic
Prior art date
Application number
PCT/US2006/047474
Other languages
French (fr)
Other versions
WO2007070547A2 (en
Inventor
Khalid K Sadozai
Charles H Sherwood
Kyle X Bui
Tamera B Gooding
Michael J Bassett
Stephen J Kennedy
Original Assignee
Anika Therapeutics Inc
Khalid K Sadozai
Charles H Sherwood
Kyle X Bui
Tamera B Gooding
Michael J Bassett
Stephen J Kennedy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anika Therapeutics Inc, Khalid K Sadozai, Charles H Sherwood, Kyle X Bui, Tamera B Gooding, Michael J Bassett, Stephen J Kennedy filed Critical Anika Therapeutics Inc
Priority to CA002633957A priority Critical patent/CA2633957A1/en
Priority to PCT/US2006/047474 priority patent/WO2007070547A2/en
Priority to EP06847587A priority patent/EP1968614A2/en
Priority to US11/638,307 priority patent/US20070203095A1/en
Publication of WO2007070547A2 publication Critical patent/WO2007070547A2/en
Publication of WO2007070547A3 publication Critical patent/WO2007070547A3/en
Priority to US13/165,196 priority patent/US8323617B2/en
Priority to US13/659,376 priority patent/US20130045945A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/729—Agar; Agarose; Agaropectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Abstract

A method of treating a subject having a musculoskeletal'disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.
PCT/US2006/047474 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid WO2007070547A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002633957A CA2633957A1 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
PCT/US2006/047474 WO2007070547A2 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
EP06847587A EP1968614A2 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US11/638,307 US20070203095A1 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US13/165,196 US8323617B2 (en) 2005-12-14 2011-06-21 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US13/659,376 US20130045945A1 (en) 2005-12-14 2012-10-24 Treatment of Arthritis and Other Musculoskeletal Disorders With Crosslinked Hyaluronic Acid

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75141405P 2005-12-14 2005-12-14
US75138105P 2005-12-14 2005-12-14
US75123705P 2005-12-14 2005-12-14
US60/751,237 2005-12-14
US60/751,414 2005-12-14
US60/751,381 2005-12-14
PCT/US2006/047474 WO2007070547A2 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

Publications (2)

Publication Number Publication Date
WO2007070547A2 WO2007070547A2 (en) 2007-06-21
WO2007070547A3 true WO2007070547A3 (en) 2007-08-16

Family

ID=54207919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/047474 WO2007070547A2 (en) 2005-12-14 2006-12-13 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

Country Status (4)

Country Link
US (3) US20070203095A1 (en)
EP (1) EP1968614A2 (en)
CA (1) CA2633957A1 (en)
WO (1) WO2007070547A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
WO2005077304A1 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Load bearing biocompatible device
US7931030B2 (en) 2004-12-30 2011-04-26 Genzyme Corporation Regimens for intra-articular viscosupplementation
EP3028677A1 (en) 2005-12-14 2016-06-08 Anika Therapeutics Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
EP2152743A2 (en) 2007-05-23 2010-02-17 Allergan, Inc. Cross-linked collagen and uses thereof
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
SI2818184T1 (en) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Compositions and methods for treating Purpura
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
AU2009288118B2 (en) 2008-09-02 2014-12-11 Allergan, Inc. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US8273725B2 (en) * 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
FR2954165B1 (en) 2009-12-18 2012-01-13 Jean-Noel Thorel INJECTABLE COMPOSITIONS FOR INTRA-ARTICULAR USE ASSOCIATING A VISCOSUPPLEMENTATION AGENT AND A FIBROBLAST GROWTH MEDIUM
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
NZ602405A (en) 2010-03-12 2014-12-24 Allergan Ind Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
PT2550027T (en) 2010-03-22 2016-08-12 Allergan Inc Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
CA3048443C (en) 2011-05-26 2021-01-05 Cartiva, Inc. Tapered joint implant and related tools
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
CA2838237C (en) 2011-06-03 2020-05-26 Allergan, Inc. Dermal filler compositions including antioxidants
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
BR112015017246B1 (en) 2013-01-23 2022-11-29 Semnur Pharmaceuticals, Inc INJECTABLE AQUEOUS PHARMACEUTICAL COMPOSITION, ITS USE AND SYRINGE
PT3613423T (en) 2013-07-10 2022-12-07 Matrix Biology Inst Compositions of hyaluronan with high elasticity and uses thereof
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
ES2761558T3 (en) 2014-09-30 2020-05-20 Allergan Ind Sas Stable hydrogel compositions including additives
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
TWI772659B (en) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 Pharmaceutical formulation
CN107427584A (en) 2015-01-28 2017-12-01 阿勒根公司 Joint fat pad preparation and its application method
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CA2981064C (en) 2015-03-31 2024-01-02 Cartiva, Inc. Carpometacarpal (cmc) implants and methods
EP3753531A1 (en) 2015-03-31 2020-12-23 Cartiva, Inc. Hydrogel implants with porous materials
WO2016168363A1 (en) 2015-04-14 2016-10-20 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
JP6948716B2 (en) 2015-09-24 2021-10-13 マトリックス バイオロジー インスティテュート Highly elastic hyaluronan composition and method of its use
NZ747413A (en) 2016-04-27 2020-09-25 Anika Therapeutics Inc Compositions for use in treating tendon degeneration
US20200368027A1 (en) 2018-01-02 2020-11-26 Cartiheal (2009) Ltd. Implantation Tool and Protocol for Optimized Solid Substrates Promoting Cell and Tissue Growth
DE102020100145B4 (en) 2020-01-07 2022-05-05 Tobias Colditz Pre-filled syringe of composition for treating inflammatory joint disease
WO2022125762A1 (en) * 2020-12-09 2022-06-16 Likarda, LLC Hydrogel microparticle-based lubricant
CN113616604B (en) * 2021-10-12 2021-12-21 北京蓝晶微生物科技有限公司 Injectable polyhydroxyalkanoate microspheres and preparation method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416250A2 (en) * 1989-08-01 1991-03-13 The Research Foundation Of State University Of New York N-acylurea and O-acylisourea derivatives of hyaluronic acid
WO2002009792A1 (en) * 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
WO2002068383A2 (en) * 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
WO2004022603A1 (en) * 2002-09-03 2004-03-18 Lg Life Sciences Ltd. Hyaluronic acid derivatives and processes for preparing the same
US20040058858A1 (en) * 2002-08-01 2004-03-25 Min Hu Configuration of glycosaminoglycans
US20050136122A1 (en) * 2003-12-22 2005-06-23 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
SE442820B (en) * 1984-06-08 1986-02-03 Pharmacia Ab GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4605691A (en) * 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4713448A (en) * 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
SE8501723L (en) * 1985-04-09 1986-10-10 Pharmacia Ab PREPARATION TO BE USED IN TREATMENT OF LED INFLAMMATION
US4808576A (en) * 1986-04-28 1989-02-28 Mobay Corporation Remote administration of hyaluronic acid to mammals
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
US4795741A (en) * 1987-05-06 1989-01-03 Biomatrix, Inc. Compositions for therapeutic percutaneous embolization and the use thereof
US5079236A (en) * 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5219360A (en) * 1991-05-10 1993-06-15 Fortis Research Corporation Mammary prosthesis fill and method of making same
US5143351A (en) * 1991-08-29 1992-09-01 Pierce Daniel H Self-locking valve spring retainer
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
IT1302534B1 (en) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR
US6288043B1 (en) * 1999-06-18 2001-09-11 Orquest, Inc. Injectable hyaluronate-sulfated polysaccharide conjugates
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US6527760B1 (en) * 2000-09-25 2003-03-04 Vijay B. Vad Out-patient joint lavage kit and protocol
ATE525076T1 (en) * 2002-10-16 2011-10-15 Arthrodynamic Technologies Animal Health Division Inc TREATMENT OF TRAUMATIC SYNOVITIS AND DAMAGED ARTicular cartilage
JP2007507431A (en) * 2003-10-09 2007-03-29 ロバート・ジョン・ペトレラ Methods for treating acute and overuse sprains and muscle differences using hyaluronic acid
JP2008507553A (en) 2004-07-23 2008-03-13 ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー Compositions and methods for viscous replenishment
US7931030B2 (en) * 2004-12-30 2011-04-26 Genzyme Corporation Regimens for intra-articular viscosupplementation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416250A2 (en) * 1989-08-01 1991-03-13 The Research Foundation Of State University Of New York N-acylurea and O-acylisourea derivatives of hyaluronic acid
WO2002009792A1 (en) * 2000-07-28 2002-02-07 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
WO2002068383A2 (en) * 2001-02-22 2002-09-06 Anika Therapeutics, Inc. Thiol-modified hyaluronan
US20040058858A1 (en) * 2002-08-01 2004-03-25 Min Hu Configuration of glycosaminoglycans
WO2004022603A1 (en) * 2002-09-03 2004-03-18 Lg Life Sciences Ltd. Hyaluronic acid derivatives and processes for preparing the same
US20050136122A1 (en) * 2003-12-22 2005-06-23 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOLTES L ET AL: "Molecular characterization of two host-guest associating hyaluronan derivatives.", BIOMEDICAL CHROMATOGRAPHY, vol. 17, no. 6, September 2003 (2003-09-01), pages 376 - 384, XP007901947, ISSN: 0269-3879 *
SOLTÉS LADISLAV ET AL: "Associating hyaluronan derivatives: a novel horizon in viscosupplementation of osteoarthritic joints.", CHEMISTRY & BIODIVERSITY MAR 2004, vol. 1, no. 3, March 2004 (2004-03-01), pages 468 - 472, XP007901948, ISSN: 1612-1880 *

Also Published As

Publication number Publication date
US8323617B2 (en) 2012-12-04
US20070203095A1 (en) 2007-08-30
US20130045945A1 (en) 2013-02-21
CA2633957A1 (en) 2007-06-21
WO2007070547A2 (en) 2007-06-21
EP1968614A2 (en) 2008-09-17
US20110312912A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
WO2007070547A3 (en) Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
WO2008102855A1 (en) Composition for treatment of cartilage disease
BR0214032A (en) Therapeutic method for treating a joint demonstrating joint cartilage degeneration, use of a viscous, buffered, stable aqueous solution, method for repairing or regenerating cartilage in a mammalian joint, and use of a mixture of chondroitin sulfate and hyaluronic acid. or pharmaceutically acceptable salts thereof
WO2005055944A3 (en) Oligosaccharide compositions and use thereof in the treatment of infection
BRPI0413728A (en) tear lipocalin muteins
BR0307420A (en) Compounds, pharmaceutical compositions and methods for preventing and / or treating mammalian disease
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
EP2628486A3 (en) Method for treating bone fracture with anti-sclerostin antibodies
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
MXPA05012011A (en) Therapeutic use of anti-cs1 antibodies.
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
PL346797A1 (en) Arylsulfonanilide ureas
WO2007006403A3 (en) Biomaterials in the form of fibres for use as medical devices in the treatment of wounds, and their production process
WO2007070546A3 (en) Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
DK1401422T3 (en) Halogen-containing composition, process for its preparation and uses thereof
WO2009015014A3 (en) Multi-step method of pain and/or inflammation treatment
WO2008143705A3 (en) Methods and compositions for rapid inactivation of proteins
HK1112721A1 (en) Tissue disruption treatment and composition for use thereof
PL1979521T3 (en) Novel method for impregnating a textile surface
EP1844779A3 (en) Tergurid/protergurid for treating chronic pain (e.g. migraine)
ATE516027T1 (en) ORAZAMID OROTAT TO PREVENT LIVER DAMAGE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2633957

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006847587

Country of ref document: EP